Understanding how Chlamydia bacteria survive and cause disease
Saturating transposon mutagenesis for Chlamydia
['FUNDING_R21'] · UNIVERSITY OF KENTUCKY · NIH-11087664
This study is looking at how the Chlamydia bacteria manage to survive and cause infections in our bodies, with the goal of finding new ways to treat it, especially since there aren't any good vaccines available yet.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11087664 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which Chlamydia trachomatis, a common bacterial pathogen, survives and causes disease within human cells. The team will use a technique called transposon mutagenesis to identify and manipulate genes that contribute to the bacteria's ability to evade the immune system and establish infections. By genetically altering the bacteria, researchers aim to uncover critical insights into their biology and pathogenicity, which could lead to new treatment strategies. This approach is particularly important given the lack of effective vaccines against Chlamydia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been diagnosed with Chlamydia trachomatis infections or are at high risk for such infections.
Not a fit: Patients who are not infected with Chlamydia or those who have already received effective treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for Chlamydia infections, enhancing reproductive health and reducing disease transmission.
How similar studies have performed: Previous research using transposon mutagenesis in other bacterial systems has shown promising results, indicating potential for success in this novel application.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FIELDS, KENNETH A — UNIVERSITY OF KENTUCKY
- Study coordinator: FIELDS, KENNETH A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.